A new Chinese-made vaccine emerged from late-stage clinical trials this week, well-positioned to help overcome a number of the obstacles that have hampered large-scale distribution of COVID-19 jabs to the world’s poorest countries, including many in Africa.
Monday’s announcement by Pakistani health advisor Faisal Sultan that CanSino Biologics’ vaccine emerged from late-stage clinical trials with a 65.7% efficacy rate. That by itself is encouraging, given that it’s far above the 50% rate required by the WHO for certification. But more importantly, the CanBio jab has a number of features that make it especially appealing for developing countries:
- Get a daily email packed with the latest China-Africa news and analysis.
- Read exclusive insights on the key trends shaping China-Africa relations.
- Full access to the News Feed that provides daily updates on Chinese engagement in Africa and throughout the Global South.